Catalysts · Trial milestones · Press
The record.
Active and upcoming clinical trial readouts, NIH-funded investigator-sponsored studies, and the regulatory roadmap to NDA filing in Q3 2028. All Phase II trials are conducted under FDA-approved INDs at major US academic medical centers.
Catalysts
Active trials and upcoming readouts.
- Q2 2026READOUT
NYU Langone Phase II PTSD trial — final readout expected
N=85 · recruitment complete · CAPS-5 primary · Blessing (PI) / Marmar (Co-PI)
- Q2 2026READOUT
Nebraska Phase II PTSD trial — interim readout
UNMC · Mathew Rizzo, MD (PI) · CAPS-5 primary · final readout Q1 2027
- Q4 2026READOUT
UCLA Phase II Smoking Cessation trial — final readout
PI: Richard De La Garza, PhD · anxiolytic + craving-reduction profile
- Q4 2026REGULATORY
FDA Pivotal Trial Initiation Meeting
Regulatory alignment ahead of multi-center pivotal PTSD trial
- Q1 2027TRIAL START
Multi-center pivotal PTSD trial — initiation
N=350 · CAPS-5 primary · readout Q3 2028 · NDA filing target Q4 2028
- Q1 2027READOUT
Yale Phase II OUD trial of Nantheia™ in OUD with chronic pain
N=120 · enrolling · PI: Joao P. De Aquino, MD
- In progressTRIAL
UCLA Phase II OUD trial — enrollment complete
N=40 · 28-day study · PI: Edythe London, PhD · final readout pending
Detailed Phase II protocols and clinical trial dossiers available under CDA to qualified institutional investors.
Press releases · News archive
Five years of clinical milestones.
Every IND clearance, first-patient-enrolled, and academic collaboration announced since program inception.
- November 14, 2025PARTNERSHIP
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD
Strategic collaboration to advance PTSD therapeutics.
- October 24, 2024TRIAL START
ANANDA Scientific and David Geffen School of Medicine, UCLA announce commencement of a clinical trial evaluating Nantheia™ for Smoking Cessation
UCLA-led Phase II Smoking Cessation trial commences.
- October 17, 2024TRIAL START
ANANDA Scientific announces a clinical trial evaluating Nantheia™ in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain
Yale-led Phase II OUD + chronic pain trial.
- March 28, 2023FIRST PATIENT
First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)
NYU Langone-led Phase II SAD trial begins enrollment.
- March 14, 2023FIRST PATIENT
UNMC and ANANDA Scientific announce First Patient Enrolled in FDA-approved clinical trial for Post-Traumatic Stress Disorder (PTSD)
UNMC Phase II PTSD trial begins enrollment.
- November 30, 2022IND APPROVAL
FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)
NYU-led SAD program receives IND clearance.
- July 26, 2022FIRST PATIENT
First Patient Enrolled in the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
UCLA-led OUD trial begins enrollment.
- May 17, 2022IND APPROVAL
UNMC and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for PTSD
UNMC PTSD program receives IND clearance.
- May 8, 2022FIRST PATIENT
First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain
NYU-led opioid-sparing trial begins enrollment (program not currently advancing).
- January 4, 2022IND APPROVAL
FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
UCLA-led OUD program receives IND clearance.
- September 29, 2021TRIAL
ANANDA Scientific and UCLA announce Clinical Trial Utilizing Liquid Structure™ for the Treatment of Opioid Use Disorder (OUD)
UCLA OUD program announced.
- June 8, 2021FIRST PATIENT
First Patient Enrolled in the Clinical Trial Evaluating Liquid Structure™ for Treatment of PTSD
NYU PTSD trial enrolls first patient.
- January 28, 2021TRIAL
Second Clinical Trial Utilizing Liquid Structure™ evaluating Opioid Sparing in Chronic Radiculopathic Pain
NYU opioid-sparing trial announced (program not currently advancing).
- January 12, 2021TRIAL
ANANDA Scientific and NYU announce Clinical Trial Utilizing Liquid Structure™ for Treatment of PTSD
NYU PTSD trial announced.
- September 8, 2020LEADERSHIP
ANANDA Scientific appoints Sohail Zaidi as its new President
Sohail Zaidi joins as President to lead clinical and corporate strategy.
- August 18, 2020LEADERSHIP
John Suh joins ANANDA Scientific's Board of Directors as Executive Director
Founder & CEO of LegalZoom joins the Board.
- January 14, 2020TRIAL
ANANDA Scientific initiates Human Clinical Trial for Liquid Structure™ Formulation
First-in-human study of nano-sized self-assembled Liquid Structure™ formulation.